The process we went through to choose some of the projects—because you're totally right, we can't do everything—is that we allowed projects that were across the spectrum from prevention, early detection, treatment. We didn't say we're going to focus here, we're going to focus there. We took all comers. In terms of the evaluation criteria, where we did say the bar will be extremely high...you get buy-in from health authorities, from the clinicians. With the economic rationale, we will base our choice of projects on not only the great science and clinical need, but on that as well. So we haven't said we're only going to concentrate on cancer or neurodegenerative work. We've taken the best possible elements, the best possible demonstrations from any field, that are really focused on being able to deliver some value to the health system in the relatively short term.
On March 5th, 2013. See this statement in context.